4 results
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Primary ObjectiveThe primary objective of this clinical investigation is to evaluate the change in marginal bone levels (DMBL) of the On1 Concept from prosthetic delivery up to 1 year after prosthetic delivery.Secondary ObjectiveThe secondary…
Objectives:Primary Objectives:1. To evaluate the efficacy of BAN2401 compared to placebo by establishing the ED90 (as defined in theprotocol) for BAN2401 on the derived Composite Clinical Score at 12 months of treatment in subjects withEarly…
The objective of this study is to assess the feasibility of HCP measurements in CRT patients during different pacing settings. We will evaluate the accuracy of LV volumetric measurements in patients with an implanted CRT. For this evaluation, LV…